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We present two real-time reverse-transcription poly-
merase chain reaction assays for a novel human 
coronavirus (CoV), targeting regions upstream of the 
E gene (upE) or within open reading frame (ORF)1b, 
respectively.  Sensitivity for upE is 3.4 copies per 
reaction (95% confidence interval (CI): 2.5–6.9 cop-
ies) or 291 copies/mL of sample.  No cross-reactivity 
was observed with coronaviruses OC43, NL63, 229E, 
SARS-CoV, nor with 92 clinical specimens containing 
common human respiratory viruses. We recommend 
using upE for screening and ORF1b for confirmation.
Introduction
Coronaviruses (CoV) are large positive-stranded RNA 
viruses causing mainly respiratory and enteric dis-
ease in a range of animals and in humans. Humans are 
known to maintain circulation of four different human 
coronaviruses (hCoV) at a global population level. 
These are part of the spectrum of agents that cause the 
common cold. The SARS-CoV constitutes a fifth hCoV, 
which was in circulation for a limited time during 2002 
and 2003, when a novel virus appeared in humans and 
caused an outbreak affecting at least 8,000 people. 
Mortality was high, at ca. 10% [1]. Symptoms matched 
the clinical picture of acute primary viral pneumonia, 
termed severe acute respiratory syndrome (SARS). 
During September 2012, health authorities were noti-
fied of two cases of severe hCoV infection caused by 
a novel virus type. Both patients had travelled, or 
resided, in Saudi Arabia. Laboratories dealing with 
each of these unlinked cases were situated in Jeddah, 
Rotterdam and London, respectively. 
In a collaborative activity co-ordinated by major 
European and national epidemic response networks 
we have developed diagnostic real-time reverse-tran-
scription polymerase chain reaction (RT-PCR) assays 
suitable for qualitative and quantitative detection of 
the new agent. Here we summarise the technical evalu-
ation and analytical performance of these assays. 
Materials and methods
Template for design of assays
A provisional genome sequence as well as an isolate of 
the new virus were obtained from author RM Fouchier 
on 24 September 2012, after public notification of the 
second case case, who was in the United Kingdom 
(UK), to be most probably infected by the same virus as 
the first case, yet unrelated. The sequence (GenBank 
accession number: JX869059 for the Rotterdam virus 
isolate, termed hCoV-EMC) served as the template for 
assay design, and the virus was used for initial valida-
tion experiments.   
Clinical samples
Respiratory swab, sputum, and endotracheal aspirate 
material was obtained during 2010–2012 from sev-
eral hospital wards of the University of Bonn Medical 
Centre. 
Cell culture
Vero cells were infected with a the cell culture isolate 
(unpublished data) at two different doses (multiplici-
ties of infection (MOI) of ca. 0.1 and ca. 10 TCID50 per 
cell) and harvested after 0, 12, 24, and 36 hours for 
RT-PCR analysis.
RNA extraction 
RNA was extracted from the samples as described ear-
lier [2] by using a viral RNA mini kit (Qiagen). Sputum 
samples were pretreated with 2× sputum lysis buffer 
(10 g of N-acetylcysteine/litre, 0.9% sodium chloride) 
for 30 minutes in a shaking incubator. Swabs were 
immersed in lysis buffer. 
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Real-time reverse-transcription 
polymerase chain reaction screening 
assay upstream of E gene (upE assay)
A 25-μl reaction was set up containing 5 μl of RNA, 
12.5 μl of 2 X reaction buffer provided with the 
Superscript III one step RT-PCR system with Platinum 
Taq Polymerase (Invitrogen; containing 0.4 mM of each 
dNTP and 3.2 mM Magnesium sulfate), 1 μl of reverse 
transcriptase/Taq mixture from the kit, 0.4 µl of a 
50 mM magnesium sulfate solution (Invitrogen – not 
provided with the kit), 1 μg of non-acetylated bovine 
serum albumin (Sigma), 400 nM concentrations of 
primer upE-Fwd (GCAACGCGCGATTCAGTT)  and primer 
upE-Rev (GCCTCTACACGGGACCCATA), as well as 200 
nM of probe upE-Prb (6-carboxyfluorescein [FAM])-
CTCTTCACATAATCGCCCCGAGCTCG-6-carboxy-N,N,N,N´-
tetramethylrhodamine [TAMRA]). All oligonucleotides 
were synthesized and provided by Tib-Molbiol, Berlin. 
Thermal cycling involved 55°C for 20 min, followed by 
95°C for 3 min and then 45 cycles of 95°C for 15 s, 58°C 
for 30 s. 
It should be mentioned that common one-step real-
time RT-PCR kits formulated for application with probes 
should all provide satisfactory results with default 
reaction mix compositions as suggested by manufac-
turers. In the particular case of our formulation the 
bovine serum albumin can be omitted if using a PCR 
instrument with plastic tubes. The component only 
serves the purpose of enabling glass capillary-based 
PCR cycling.  
Real-time reverse-transcription polymerase 
chain reaction confirmatory assay 
(open reading frame (ORF)1b gene)
The assay had the same conditions as for the upE 
RT-PCR, except primer and probe sequences were 
ORF1b-Fwd (TTCGATGTTGAGGGTGCTCAT), primer 
ORF1b-Rev (TCACACCAGTTGAAAATCCTAATTG), 
and probe ORF1b-Prb (6-carboxyfluorescein 
[FAM])- CCCGTAATGCATGTGGCACCAATGT-6-carboxy-
N,N,N,N´-tetramethylrhodamine [TAMRA]). This target 
gene did not overlap with those of known pan-CoV 
assays [3-5].
In-vitro transcribed RNA controls
PCR fragments covering the target regions of both 
assays, and some additional flanking nucleo-
tides (‘peri-amplicon fragments‘), were gener-
ated using primers CTTCTCATGGTATGGTCCCTGT 
and AAGCCATACACACCAAGAGTGT for the upE 
assay, and CGAGTGATGAGCTTTGCGTGA and 
CCTTATGCATAAGAGGCACGAG for the ORF1b assay. 
Products were ligated into pCR 4 plasmid vectors and 
cloned in Escherichia coli by means of a pCR 4-TOPO TA 
Figure 1
Replication of hCoV-EMC monitored by the upE and ORF1b RT-PCR assays, 2012 
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points (after 0, 12, 24, and 36 hours) were tested by the upE and ORF1b RT-PCR assays. 
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cloning reagent set (Invitrogen). Plasmids were exam-
ined for correct orientation of inserts by PCR, purified, 
and re-amplified with plasmid-specific primers from 
the reagent set to reduce the plasmid background in 
subsequent in vitro transcription. Products were tran-
scribed into RNA with the MegaScript T7 in vitro tran-
scription reagent set (Ambion). After DNase I digestion, 
RNA transcripts were purified with Qiagen RNeasy col-
umns and quantified photometrically. All transcript 
dilutions were carried out in nuclease-free water con-
taining 10 µg/mL carrier RNA (Qiagen). 
Determination of analytical sensitivities 
of real-time reverse-transcription 
polymerase chain reaction methods
Series of eight parallel reactions per concentration step 
were prepared and tested by the respective RT-PCR 
to determine concentration-dependent hit rates. Hit 
rates were subjected to probit regression analysis in 
StatgraphicsPlus software (version 5.0; Statistical 
Graphics Corp.).
Specificity of the assays
Assay specificity was determined using high-titred 
virus stock solutions, as well as clinical samples known 
to contain respiratory viruses. All material stemmed 
from the in-house strain and sample collection of 
University of Bonn, Institute of Virology. Identities and 
virus RNA concentrations were re-confirmed by specific 
real-time RT-PCRs for each virus before the experiment. 
Measured RNA concentrations are listed below along 
with the recorded stock virus titres.  
Results
Upon scanning of a provisional genome assembly, a 
region upstream of the putative E gene was identified 
as a particularly suitable target region for a real-time 
RT-PCR assay.  The assay designed for this region is 
hereafter referred to as the upE-assay. A confirmatory 
test was designed in the open reading frame 1b (termed 
the ORF1b assay). This target gene did not overlap with 
those of known pan-CoV assays [3-5]. 
In order to obtain an estimate of the end point sen-
sitivity of the assays, they were applied to cell cul-
ture-derived virus stock. The virus had a titre of 
1.26 x 107 median tissue culture infective dose (TCID50)/
mL. In limiting dilution experiments, the upE and ORF1b 
assays detected down to 0.01 and 0.1 TCID50 per reac-
tion, respectively. The discrepancy between assays 
might be due to release of subgenomic RNA after onset 
of cytopathogenic effect (CPE) in cell culture, including 
the upE target fragment. As shown in Figure 1, PCRs 
on these samples indicated no divergence between the 
assays after onset of CPE (observed at 24h onwards). 
However, both assays deviated from each other by 
constant numbers of Ct values over the full duration of 
incubation, including time 0 (T0) when the cells were 
just infected and when no subgenomic RNA could have 
been present. It was concluded that the higher Ct val-
ues at each time point, and the lower dilution end point 
Figure 2
Probit regression analysis to determine limit of detection 
for the upE and ORF1b assays, 2012
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for the ORF1b assay indicated that this assay had a 
lower sensitivity. 
A more detailed assessment of technical sensitivity can 
be achieved using quantified, in-vitro transcribed RNA 
derived from the peri-amplicon region of each assay. 
These transcripts were generated and tested in serial 
ten-fold dilution experiments. Detection end points 
were two copies per reaction for the upE assay, and 10 
copies per reaction for the confirmatory, ORF1b gene, 
assay. To obtain a statistically robust assessment of 
Limit Of Detection (LOD), transcripts were also tested 
in multiple parallel reactions in smaller dilution inter-
vals above and below the end-point PCR limits. The 
results in terms of the fraction of positive reactions at 
each concentration were subjected to probit regression 
analysis and plotted as shown in Figure 2, where panel 
A shows the upE assay and panel B the ORF1b assay. 
The resulting LODs are summarised in Table 1. Based 
on the upE assay with a detection limit of 3.4 copies 
per reaction, and a cell-culture endpoint equivalent 
to 0.01 TCID50 per reaction, it was calculated that the 
RNA/infectious unit ratio of the virus stock must have 
been ca. 29 (100/3.4). 
To exclude non-specific reactivity of oligonucleotides 
among each other, all formulations were tested 40 
times in parallel with assays containing water and no 
other nucleic acids except the provided oligonucleo-
tides. In none of these reactions was any positive sig-
nal seen. Cross-reactivity with known, heterospecific 
human CoVs was excluded by testing high-titred cell 
culture materials as summarised in Table 1. It should 
be noted that the unculturable hCoV-HKU1 was not 
included in these experiments. 
To obtain a more clinically relevant figure on assay 
specificity, the assays were applied on 92 original 
clinical samples in which other respiratory viruses 
had already been detected during routine respiratory 
screening at Bonn University Medical Centre. These 
samples were prepared using the Qiagen Viral RNA kit, 
a formulation widely used to extract RNA in clinical lab-
oratories. Of note, the tested panel included four sam-
ples containing hCoV-HKU1, which was not available as 
cultured virus stock. In total, none of the 92 original 
clinical samples as presented in Table 2, containing a 
wide range of respiratory viruses, gave any detection 
signal with either assay while positive controls were 
readily detected. It was concluded that the assay could 
be reliably applied to clinical samples. 
Preliminary testing was also done on a patient hospi-
talised with acute infection during preparation of this 
report (Authors R Gopal and M Zambon, own unpub-
lished observations). Both assays provided very clear 
amplification signal on various clinical samples. The 
upE assay again appeared more sensitive than the 
ORF1b assay. 
Discussion
Here we provide the technical background data for 
RT-PCR assays developed in rapid response to the 
emergence of a novel human CoV (GenBank accession 
number: JX869059 for the Rotterdam virus isolate, 
termed hCoV-EMC). 
Cell culture-derived virus is a useful source of refer-
ence material for the evaluation of molecular detection 
assays. However, detection end points determined on 
cell culture-derived virus are difficult to correlate to 
virus titre. Reasons include the discrepancy between 
Experiment upE assay ORF1b assay
Detection end point for cell culture-derived virus 0.01 TCID50/reaction 0.1 TCID50/reaction
Technical LOD 3.4 RNA copies/reaction  (95% CI: 2.5–6.9 copies/reaction)
64 RNA copies/reaction
(95% CI: 47–126 copies/reaction)
Cross-reactivity with hCoV-229E No reactivity with virus containing 10
5 PFU/mL 
(3 x 109 RNA copies/mL)
Cross-reactivity with hCoV-NL63 No reactivity with virus containing 10
6 PFU/mL
(4 x 109 copies/mL)
Cross-reactivity with hCoV-OC43 No reactivity with virus containing 5 X 10
5 PFU/mL
(3 x 1010 copies/mL)
Cross-reactivity with SARS-CoV No reactivity with virus containing 3 x 10
6 PFU/mL
(5 x 1010 copies/mL)
CI: confidence interval CoV: corona virus; LOD: limit of detection; ORF: open reading frame; PFU: plaque forming units; TCID50: median tissue 
culture infective dose; upE: upstream of the E gene.
Table 1
Results of sensitivity and specificity tests for hCoV-EMC assays, 2012*
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infectious viral particles and the number of copies 
of viral RNA, as well as the imbalance between viral 
genomic and subgenomic transcripts in the particular 
case of CoVs. This is important for laboratories using 
cell-cultured virus as reference, but also in the clinical 
setting. For example, SARS-CoV assays targeting struc-
tural protein genes tend to be slightly more sensitive 
than ORF1b-based assays when applied to clinical sam-
ples [6]. For the novel virus the ratio of RNA copies per 
infectious unit was ca. 29, while little imbalance seems 
to exist between genomic and subgenomic RNA in Vero 
cells up to 36 h post infection. 
While we are not addressing the issue of quantita-
tive PCR in this report, it should be mentioned that 
the availability of synthetic RNA standards enables 
immediate implementation of quantitative virus detec-
tion that is essential for case management and public 
health. Quantitative virus data can help assess the 
height and duration of virus excretion, and can also be 
useful as an early and robust parameter for the success 
of treatment [2,7,8]. Here we have used synthetic RNA 
to determine technical limits of detection in the style 
of standards applied by industry, taking inter-assay 
variation into account and providing statistically robust 
detection end points based on physically quantified 
target genes, which is impossible to achieve on cell-
cultured virus. It is important to note that the detec-
tion limits we describe here are expressed as copies 
per reaction. We have chosen not to translate these 
numbers into other terms such as ’copies per ml of 
sputum‘, ’copies per swab sample‘, or ’copies per gram 
of faeces‘. Such transformations vary greatly between 
different RNA extraction methods and clinical materi-
als. However, we can project that the level of sensi-
tivity, particularly for the upE assay, is very similar 
to those levels achieved with most advanced RT-PCR 
assays developed for the SARS-CoV [6,8]. For example, 
the Qiagen Viral RNA kit with an input volume of 140 
µl of sample and an elution volume of 60 µl as recom-
mended by the manufacturer involves a conversion 
factor of 85.7 between copies per reaction and copies 
per mL of sample. The upE assay should thus detect 
as little as ca. 291 copies per mL of sputum with 95% 
certainty. For solid samples such as swabs, which can 
be dipped into the lysis buffer, the resulting conversion 
factor is 12, resulting in a projected capability of the 
assay to detect as little as ca. 41 copies per swab with 
95% certainty.  
In this regard it is highly important to remember practi-
cal experiences made with SARS-CoV detection. Even 
with the highest levels of RT-PCR sensitivity it turned 
out that not all patients retrospectively shown to sero-
convert could be diagnosed by RT-PCR in the acute 
phase of disease [6,8,9]. This has been ascribed to the 
fact the SARS-CoV replication occurs predominantly in 
the lower respiratory tract due to the anatomical locali-
sation of its entry receptor, Angiotensin-converting 
enzyme 2 (ACE2). Should the novel virus use the same 
receptor, we might see a similar distribution of virus, 
and similar challenges in clinical application of molec-
ular diagnostics. Studies of virus concentration in 
clinical samples are underway to address these highly 
critical issues. 
 
Specificity is a very important issue in rare, highly criti-
cal virus infections for which a broad number of differ-
ential diagnoses exist. The risk associated with false 
positive PCR results posed a challenge in development 
of the assays described here. First, real-time PCR can 
yield artificial signals due to technical interference 
of oligonucleotides involved in the assay (resembling 
primer dimers in which probe sequences participate). 
These may be observed at infrequent intervals due to 
the statistical nature of nonspecific random molecu-
lar interactions. We have taken care to exclude the 
occurrence of those signals by testing large series of 
water-containing assays. Second, any virus detection 
assay might cross-react with related viruses, and there 
is worldwide circulation of four different human CoVs. 
Viral stock solutions were tested in order to exclude 
cross-reactivity even on high-titred materials. In spite 
of the favourable outcome of this experiment, it should 
Virus Number of  samples tested
Parainfluenza virus
    Parainfluenza 1 virus 5
    Parainfluenza 2 virus 5
    Parainfluenza 3 virus 8
    Parainfluenza 4 virus 1
Respiratory syncytial virus 7
Human metapneumovirus 8
Coronavirus
    hCoV-NL63 6
    hCoV-OC43 4
    hCoV-229E 2
    hCoV-HKU1 4
Rhinovirus 8
Enterovirus 9
Adenovirus 8
Human Parechovirus
    Type 1 5
    Type 3 3
Influenza A (H1N1,  H3N2) 9
Influenza B 2
Total 92
Table 2
Known respiratory viruses in clinical samples used for 
testing the specificity of hCoV-EMC assays, 2012
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be mentioned that of the two assays investigated, the 
target gene of the ORF1b-based assay was most con-
served between CoV. The genetic range of known CoV 
from animals is larger than those human viruses tested 
here. Theoretical comparisons between genomes of 
these viruses and our ORF1b assay suggested no risk 
of significant cross-reactivity (not shown). However, in 
absence of further investigation we tend to recommend 
using the upE assay for case management. This is also 
due to the lower sensitivity of the ORF1b assay.
The final proof of assay specificity was provided in a 
set of clinical samples that was assembled to realis-
tically reflect the composition of patient groups pre-
senting with Acute respiratory infections (ARI). Of note, 
also the four ‘common-cold coronaviruses’ hCoV-NL63, 
-229E, -OC43, and -HKU1 were included in this panel. 
Consequentially, we can say from these data that typi-
cal human CoV will not cross-react with the assay, even 
under adverse conditions such as those created by the 
additional presence of patient-derived nucleic acid and 
other components typical of clinical samples that may 
all interfere with the performance of PCR. 
The open availability of proven diagnostic assays early 
in an epidemic is useful in order to equip and prepare 
public health laboratories efficiently [10,11]. However, 
there is a number of caveats associated with the wide 
and largely uncontrolled provision of such technol-
ogy during the very early phase of an epidemic. In this 
phase public health authorities around the world have 
to monitor the development of case statistics in order 
to make projections and attain epidemic risk assess-
ment. The notification of false positive laboratory 
results can be highly detrimental during this phase of 
the epidemic. 
The authors of this paper will provide in-vitro tran-
scribed RNA controls to health professionals (refer to 
Acknowledgements section) but will not be able to pro-
vide intense technical advice.  Authors will follow the 
policy of providing only one control, namely that for the 
upE assay, in order to minimise opportunities for acci-
dental laboratory contamination. If laboratories find 
patient samples positive by the upE assay and control, 
they can conduct confirmatory testing using the ORF1b 
assay. A positive result in this test would most likely 
not be due to contamination. Of note, the target gene 
of our ORF1b assay does not overlap with that of other, 
so-called ‘pan-CoV’ assays [3-5], excluding the possi-
bility of contaminating our assay with high-titred con-
trols or PCR products from these assays. 
In this light we should mention that we have been 
working on an N gene-based assay as well, but our 
experience with testing clinical material strongly sug-
gests N-gene assays should not be used for diagnostic 
application for the time being, i.e., as long as no direct 
sequence information of the N gene is available from 
clinical samples.
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